116 related articles for article (PubMed ID: 11369642)
1. Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia.
Deng M; Daley GQ
Blood; 2001 Jun; 97(11):3491-7. PubMed ID: 11369642
[TBL] [Abstract][Full Text] [Related]
2. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.
Hao SX; Ren R
Mol Cell Biol; 2000 Feb; 20(4):1149-61. PubMed ID: 10648600
[TBL] [Abstract][Full Text] [Related]
3. ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells.
Tamura T; Kong HJ; Tunyaplin C; Tsujimura H; Calame K; Ozato K
Blood; 2003 Dec; 102(13):4547-54. PubMed ID: 12933588
[TBL] [Abstract][Full Text] [Related]
4. Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2.
Burchert A; Cai D; Hofbauer LC; Samuelsson MK; Slater EP; Duyster J; Ritter M; Hochhaus A; Müller R; Eilers M; Schmidt M; Neubauer A
Blood; 2004 May; 103(9):3480-9. PubMed ID: 14656881
[TBL] [Abstract][Full Text] [Related]
5. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias.
Schmidt M; Nagel S; Proba J; Thiede C; Ritter M; Waring JF; Rosenbauer F; Huhn D; Wittig B; Horak I; Neubauer A
Blood; 1998 Jan; 91(1):22-9. PubMed ID: 9414265
[TBL] [Abstract][Full Text] [Related]
6. Interferon consensus sequence binding protein (ICSBP) decreases beta-catenin activity in myeloid cells by repressing GAS2 transcription.
Huang W; Zhou W; Saberwal G; Konieczna I; Horvath E; Katsoulidis E; Platanias LC; Eklund EA
Mol Cell Biol; 2010 Oct; 30(19):4575-94. PubMed ID: 20679491
[TBL] [Abstract][Full Text] [Related]
7. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
Zhang X; Ren R
Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
[TBL] [Abstract][Full Text] [Related]
8. Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha.
Schmidt M; Hochhaus A; Nitsche A; Hehlmann R; Neubauer A
Blood; 2001 Jun; 97(11):3648-50. PubMed ID: 11369663
[TBL] [Abstract][Full Text] [Related]
9. Bcr-abl regulates Stat5 through Shp2, the interferon consensus sequence binding protein (Icsbp/Irf8), growth arrest specific 2 (Gas2) and calpain.
Hjort EE; Huang W; Hu L; Eklund EA
Oncotarget; 2016 Nov; 7(47):77635-77650. PubMed ID: 27769062
[TBL] [Abstract][Full Text] [Related]
10. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
He L; Feng H; Raymond A; Kreeger M; Zeng Y; Graner M; Whitesell L; Katsanis E
Cancer Immunol Immunother; 2001 Mar; 50(1):31-40. PubMed ID: 11315508
[TBL] [Abstract][Full Text] [Related]
11. ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines.
Nardi V; Naveiras O; Azam M; Daley GQ
Blood; 2009 Apr; 113(16):3813-20. PubMed ID: 19171873
[TBL] [Abstract][Full Text] [Related]
12. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
[TBL] [Abstract][Full Text] [Related]
13. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia.
Lin H; Monaco G; Sun T; Ling X; Stephens C; Xie S; Belmont J; Arlinghaus R
Oncogene; 2005 May; 24(20):3246-56. PubMed ID: 15735695
[TBL] [Abstract][Full Text] [Related]
14. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
15. Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells.
Zeng Y; Graner MW; Thompson S; Marron M; Katsanis E
Blood; 2005 Mar; 105(5):2016-22. PubMed ID: 15374884
[TBL] [Abstract][Full Text] [Related]
16. Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice.
Peters DG; Klucher KM; Perlingeiro RC; Dessain SK; Koh EY; Daley GQ
Oncogene; 2001 May; 20(21):2636-46. PubMed ID: 11420675
[TBL] [Abstract][Full Text] [Related]
17. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
18. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.
Koschmieder S; Göttgens B; Zhang P; Iwasaki-Arai J; Akashi K; Kutok JL; Dayaram T; Geary K; Green AR; Tenen DG; Huettner CS
Blood; 2005 Jan; 105(1):324-34. PubMed ID: 15331442
[TBL] [Abstract][Full Text] [Related]
19. Altered development and cytokine responses of myeloid progenitors in the absence of transcription factor, interferon consensus sequence binding protein.
Scheller M; Foerster J; Heyworth CM; Waring JF; Löhler J; Gilmore GL; Shadduck RK; Dexter TM; Horak I
Blood; 1999 Dec; 94(11):3764-71. PubMed ID: 10572090
[TBL] [Abstract][Full Text] [Related]
20. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene.
Holtschke T; Löhler J; Kanno Y; Fehr T; Giese N; Rosenbauer F; Lou J; Knobeloch KP; Gabriele L; Waring JF; Bachmann MF; Zinkernagel RM; Morse HC; Ozato K; Horak I
Cell; 1996 Oct; 87(2):307-17. PubMed ID: 8861914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
